OncoCyte Performance dei guadagni passati
Il passato criteri di controllo 0/6
OncoCyte's earnings have been declining at an average annual rate of -3.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 11.1% per year.
Informazioni chiave
-3.3%
Tasso di crescita degli utili
21.0%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 17.0% |
Tasso di crescita dei ricavi | 11.1% |
Rendimento del capitale proprio | -159.2% |
Margine netto | -3,597.7% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?
Jan 25OncoCyte signs an at-the-market agreement to sell $50M of common stock
Jun 14Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt
Jun 02Ripartizione dei ricavi e delle spese
Come OncoCyte guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 1 | -37 | 12 | 10 |
31 Mar 24 | 1 | -40 | 13 | 9 |
31 Dec 23 | 2 | -26 | 14 | 9 |
30 Sep 23 | 1 | -22 | 16 | 8 |
30 Jun 23 | 1 | -17 | 18 | 7 |
31 Mar 23 | 1 | -11 | 20 | 7 |
31 Dec 22 | 1 | -19 | 22 | 7 |
30 Sep 22 | -1 | -22 | 14 | 2 |
30 Jun 22 | 0 | -34 | 16 | 3 |
31 Mar 22 | 1 | -43 | 19 | 3 |
31 Dec 21 | 2 | -44 | 20 | 5 |
30 Sep 21 | 5 | -35 | 29 | 10 |
30 Jun 21 | 4 | -28 | 26 | 10 |
31 Mar 21 | 2 | -26 | 23 | 11 |
31 Dec 20 | 1 | -30 | 22 | 9 |
30 Sep 20 | 1 | -32 | 22 | 10 |
30 Jun 20 | 0 | -30 | 20 | 9 |
31 Mar 20 | 0 | -26 | 19 | 8 |
31 Dec 19 | 0 | -22 | 15 | 7 |
30 Sep 19 | 0 | -19 | 13 | 5 |
30 Jun 19 | 0 | -17 | 11 | 6 |
31 Mar 19 | 0 | -16 | 9 | 6 |
31 Dec 18 | 0 | -16 | 9 | 6 |
30 Sep 18 | 0 | -15 | 8 | 7 |
30 Jun 18 | 0 | -19 | 12 | 7 |
31 Mar 18 | 0 | -18 | 11 | 7 |
31 Dec 17 | 0 | -19 | 12 | 7 |
30 Sep 17 | 0 | -19 | 11 | 7 |
30 Jun 17 | 0 | -14 | 7 | 7 |
31 Mar 17 | 0 | -13 | 7 | 6 |
31 Dec 16 | 0 | -11 | 5 | 6 |
30 Sep 16 | 0 | -12 | 6 | 6 |
30 Jun 16 | 0 | -11 | 6 | 5 |
31 Mar 16 | 0 | -10 | 5 | 5 |
31 Dec 15 | 0 | -9 | 4 | 5 |
30 Sep 15 | 0 | -7 | 2 | 4 |
30 Jun 15 | 0 | -5 | 1 | 4 |
31 Mar 15 | 0 | -5 | 1 | 4 |
31 Dec 14 | 0 | -5 | 1 | 4 |
Guadagni di qualità: OCX is currently unprofitable.
Margine di profitto in crescita: OCX is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: OCX is unprofitable, and losses have increased over the past 5 years at a rate of 3.3% per year.
Accelerare la crescita: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: OCX has a negative Return on Equity (-159.19%), as it is currently unprofitable.